June 27, 2012
/PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of
to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform (known as ThermoVax
). Synthetic adjuvants are immunologically active compounds that are added to vaccines to aid in the induction of enhanced protective immune responses. IDRI has state of the art expertise in developing and formulating a range of adjuvants that have proven capable of enhancing the level and breadth of cellular and humoral immune responses to a variety of vaccine antigens. The combination of these technologies has the potential to result in vaccines with robust characteristics for long-term stability and rapid onset of protective immunity, desired features of vaccines that would be stockpiled for emergency use.
The first developmental objective of the collaboration is to assess the combination of one of IDRI's adjuvant compounds that has been shown to enhance the generation of high titer neutralizing antibodies to anthrax toxin with Soligenix's second generation DNI (Dominant Negative Inhibitor) subunit protein anthrax vaccine candidate, known as VeloThrax
is Soligenix's hyperimmunogenic derivative of anthrax rPA (recombinant protective antigen), a candidate vaccine to protect against anthrax disease. Concurrently, the second developmental objective is to assess the combination of an IDRI adjuvant with formulations of RiVax
, Soligenix's vaccine against ricin toxin under development. The goal for both vaccines is to achieve stable products that will promote rapid onset of protective immunity in humans to minimize the number of vaccinations required for protective immunity.
"IDRI is enthusiastic about working with Soligenix to support their efforts in developing their anthrax and ricin vaccine candidates, and are highly confident that IDRI's adjuvant technology can help build effective vaccines," said Darrick Carter PhD, IDRI's Vice President of Adjuvant Technology. "These new candidate vaccines could be the critical solution in providing protection to people in the event there is a bioterror threat from the release of anthrax or ricin toxins."